Know Cancer

or
forgot password

Investigating Natalizumab Through Further Observational Research and Monitoring


N/A
18 Years
N/A
Open (Enrolling)
Both
Crohn's Disease

Thank you

Trial Information

Investigating Natalizumab Through Further Observational Research and Monitoring


Inclusion Criteria:



- CD patients prescribed TYSABRI® within the TOUCH prescribing program Exclusion
Criteria:

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Incidence of serious and/or clinically significant infections, malignancies, and other SAEs in patients with CD treated with TYSABRI®

Authority:

United States: Food and Drug Administration

Study ID:

ELN100226-CD451

NCT ID:

NCT00707512

Start Date:

June 2008

Completion Date:

Related Keywords:

  • Crohn's Disease
  • Crohn Disease

Name

Location

United BioSource CorporationMorgantown, West Virginia  26505